You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
A pair of lawyers familiar with the case said that while ACLA might not win the legal battle, its lawsuit could aid efforts to get a legal fix to the law.
Abbott highlighted its next-generation Alinity platforms, and Caris discussed its plans to provide precision oncology services.
The company said it plans to use the platform for research and development of companion diagnostics and in other oncology and precision medicine applications.
The firms have agreed to develop infectious disease and women's heath testing assays using SpeeDx's proprietary technology.
While legislation and lawsuits sought to blunt PAMA's impact, labs also employed new technologies and strategies to cope with anticipated price cuts.
The firm is offering total consideration of $1,018.36 per $1,000 for notes tendered by Dec. 2, which includes an early tender premium of $30 per $1,000.
News items from the in vitro diagnostics industry for the week of Nov. 18, 2019.
The offering consists of two tranches, $400 million of 2.3 percent senior notes due 2024 and $650 million of 2.95 percent senior notes due 2029.
The firm said that it will use proceeds from the sale to purchase or repay other notes or loans, including up to $300 million in outstanding senior notes.
Comments from Quest suggest lab buys are becoming more complex while others suggest hospitals will remain reluctant to sell so long as premium pricing persists.